If Everything Is Psychedelic,Then Nothing Is: A Response to O'Donnell et al. and Lepow et al.

O'Donnell KC , Roberts DE , Ching THW , et al. What Is in a Name? The Many Meanings of “Psychedelic”. Psychedelic Med, 2023; 1(4):187–189; DOI: 10.1089/psymed.2023.0011.

Lepow L , Kronman H , Yehuda R . A Heuristic Approach: Against Consensus Definitions of Psychedelics. Psychedelic Med, 2023; 1(4):190–194; DOI: 10.1089/psymed.2023.0031.

Osmond H . A Review of The Clinical Effects of Psychotomimetic Agents. Ann N Y Acad Sci, 1957; 66(3):418–434]; https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.1957.tb40738.x [Last accessed: November 28, 2023].

Pollan M. How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Penguin Press: New York; 2018; p. 164.

Nichols DE , Hoffman AJ , Oberlender RA , et al. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: Representatives of a novel therapeutic class. J Med Chem, 1986; 29(10):2009–2015.

Moreno FA , Wiegand CB , Taitano EK , et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry, 2006; 67(11):1735–1740.

Griffiths RR , Richards WA , McCann U , et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl), 2006; 187(3):268–283.

Grob CS , Danforth AL , Chopra GS , et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 2011; 68(1):71–78.

Griffiths RR , Johnson MW , Carducci MA , et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197.

Ross S , Bossis A , Guss J , et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol, 2016; 30(12):1165–1180.

Bogenschutz MP , Forcehimes AA , Pommy JA , et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol, 2015; 29(3):289–299.

Johnson MW , Garcia-Romeu A , Cosimano MP , et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol, 2014; 28(11):983–992.

Carhart-Harris RL , Williams TM , Sessa B , et al. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: A preliminary investigation of tolerability. J Psychopharmacol, 2011; 25(11):1562–1567.

Carhart-Harris RL , Erritzoe D , Williams T , et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A, 2012; 109(6):2138–2143.

Carhart-Harris RL , Leech R , Williams TM , et al. Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry, 2012; 200:238–244.

Carhart-Harris RL , Leech R , Erritzoe D , et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull, 2013; 39(6):1343–1351.

Yaden DB , Haidt J , Hood RW Jr , et al. The varieties of self-transcendent experience. Rev Gen Psychol, 2017; 21(2):143–160.